TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07331272: An Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammato

Sponsor: Nanjing Legend Biotech Co. · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 38 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$3,823,980

Rescue Site Savings

+$2,533,680

Unlock Full NCT07331272 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07331272 Rescue Dossier →